clinical trial · NCT05460325
A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)
Takeda·phase3·completed·n = 20
Hereditary Angioedema (HAE)Lanadelumab
brief summary
The main aim of this study is to evaluate the safety of lanadelumab in Chinese participants with HAE. Participants will be treated with lanadelumab for 26 weeks.
started
Jun 22, 2022
primary completion
Nov 28, 2023
completion
Nov 28, 2023
last updated
Dec 13, 2024
official title
A Multi-center, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Lanadelumab (SHP643) in Chinese Subjects With Hereditary Angioedema
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol